Claims for Patent: 8,580,253

Summary for Patent: 8,580,253

Title:	Immunomodulating compositions and methods of use
Abstract:	This invention is directed to .beta.-1-6-glucans, compositions and devices comprising the same, and methods of use thereof in modulating immune responses. The .beta.-1-6-glucans of certain embodiments of the invention are enriched for O-acetylated groups and/or conjugated to a solid support or linked to a targeting moiety.
Inventor(s):	Rubin-Bejerano; Ifat (Belmont, MA), Fink; Gerald R. (Chestnut Hill, MA), Abeijon; Claudia (Worcester, MA), Kohane; Danial S. (Newton, MA), Fuller; Jason E. (Boston, MA), Langer; Robert S. (Newton, MA)
Assignee:	Whitehead Institute (Cambridge, MA) Massachusetts Institute of Technology (Cambridge, MA) Trustees of Boston University (Boston, MA) The General Hospital Corporation (Boston, MA)
Application Number:	12/513,830
Patent Claims:	1. A composition comprising .beta.-1-6-glucan linked to a targeting moiety that targets a neoplastic cell, a pre-neoplastic cell or a component thereof wherein said targeting moiety is an antibody or antigen-binding fragment thereof. 2. The composition of claim 1, wherein said .beta.-1-6-glucan is isolated or derived from a lichen, a fungus, or a yeast. 3. The composition of claim 1, wherein said .beta.-1-6-glucan is genetically engineered, or chemically synthesized or acetylated. 4. The composition of claim 1, wherein the composition is a pharmaceutical composition, a food or food product, a food supplement, or a cosmetic composition. 5. A composition comprising .beta.-1-6-glucan linked to an antibody or antigen-binding fragment thereof. 6. The composition of claim 1, wherein said targeting moiety is a monoclonal antibody or a human antibody. 7. The composition of claim 1, wherein said targeting moiety is a humanized antibody. 8. The composition of claim 1, wherein said targeting moiety is selected from the group consisting of Alemtuzumab, Bevacizumab, Cetuximab, Gemtuzumab, Ibritumomab, Panitumumab, Rituximab, Tositumomab, Trastuzumab, and Palivizumab. 9. The composition of claim 1, wherein said targeting moiety is a Fab fragment, Fab' fragment, (Fab').sub.2 fragment, Fv fragment, a single chain antibody or a peptide coding for a single complementarity-determining region. 10. A composition comprising .beta.-1-6-glucan linked to a targeting moiety that binds to a tumor antigen wherein said targeting moiety is an antibody or antigen-binding fragment thereof. 11. The composition of claim 1, wherein said targeting moiety is linked to said .beta.-1-6-glucan via a covalent linkage. 12. The composition of claim 1, wherein said targeting moiety is linked to said .beta.-1-6-glucan via a non-covalent linkage. 13. The composition of claim 1, wherein said targeting moiety is linked to said .beta.-1-6-glucan via a linker molecule. 14. The composition of claim 1, wherein the composition is substantially free of .beta.-1-3-glucan. 15. The composition of claim 1, wherein at least 90% of the dry weight of glucan contained in the composition is .beta.-1-6-glucan. 16. The composition of claim 1, wherein said .beta.-1-6-glucan is processed. 17. The composition of claim 1, wherein said .beta.-1-6-glucan is isolated or derived from Umbilicariaceae. 18. The composition of claim 1, wherein said targeting moiety is an antibody or antigen-binding fragment thereof that is linked to said .beta.-1-6-glucan via a covalent linkage. 19. The composition of claim 1, wherein the composition promotes complement-mediated lysis of the neoplastic or pre-neoplastic cell when contacted in vitro with the neoplastic cell or pre-neoplastic cell in the presence of serum. 20. The composition of claim 1, wherein the composition promotes deposition of C3 or a C3 proteolytic fragment when contacted in vitro with the neoplastic cell or pre-neoplastic cell in the presence of serum. 21. The composition of claim 20, wherein the C3 proteolytic fragment is selected from the group consisting of C3b, C3d and a combination thereof. 22. The composition of claim 1, wherein the composition promotes deposition of IgG when contacted in vitro with the neoplastic cell or pre-neoplastic cell in the presence of serum. 23. The composition of claim 1, wherein the composition promotes recruitment of neutrophils when contacted in vitro with the neoplastic cell or pre-neoplastic cell in the presence of serum and neutrophils. 24. The composition of claim 5, wherein the composition promotes complement-mediated lysis of a cell that is targeted by the antibody or antigen-binding fragment thereof when contacted in vitro with the cell in the presence of serum. 25. The composition of claim 5, wherein the composition promotes deposition of C3 or a C3 proteolytic fragment when contacted in vitro, in the presence of serum, with a cell that is targeted by the antibody or antigen-binding fragment thereof. 26. The composition of claim 25, wherein the C3 proteolytic fragment is selected from the group consisting of C3b, C3d and a combination thereof. 27. The composition of claim 5, wherein the composition promotes deposition of IgG when contacted in vitro, in the presence of serum, with a cell that is targeted by the antibody or antigen-binding fragment thereof. 28. The composition of claim 5, wherein the composition promotes recruitment of neutrophils when contacted in vitro, in the presence of serum and neutrophils, with a cell that is targeted by the antibody or antigen-binding fragment thereof. 29. The composition of claim 10, wherein the composition promotes complement-mediated lysis of a cell that expresses the tumor antigen when contacted in vitro with the cell in the presence of serum. 30. The composition of claim 10, wherein the composition promotes deposition of C3 or a C3 proteolytic fragment when contacted in vitro, in the presence of serum and neutrophils, with a cell that expresses the tumor antigen. 31. The composition of claim 30, wherein the C3 proteolytic fragment is selected from the group consisting of C3b, C3d and a combination thereof. 32. The composition of claim 10, wherein the composition promotes deposition of IgG when contacted in vitro, in the presence of serum, with a cell that expresses the tumor antigen. 33. The composition of claim 10, wherein the composition promotes recruitment of neutrophils when contacted in vitro, in the presence of serum, with a cell that expresses the tumor antigen. 34. The composition of claim 1, wherein less than 10% of the total glucan in the composition, by weight, is .beta.-1-3-glucan. 35. The composition of claim 5, wherein less than 10% of the total glucan in the composition, by weight, is .beta.-1-3-glucan. 36. The composition of claim 5, wherein the composition is substantially free of .beta.-1-3-glucan. 37. The composition of claim 5, wherein at least 90% of the dry weight of glucan contained in the composition is .beta.-1-6-glucan. 38. The composition of claim 10, wherein less than 10% of the total glucan in the composition, by weight, is .beta.-1-3-glucan. 39. The composition of claim 10, wherein the composition is substantially free of .beta.-1-3-glucan. 40. The composition of claim 10, wherein at least 90% of the dry weight of glucan contained in the composition is .beta.-1-6-glucan. 41. The composition of claim 5, wherein said antibody is a monoclonal antibody or a human antibody. 42. The composition of claim 5, wherein said antibody is a humanized antibody. 43. The composition of claim 5, wherein said antibody is selected from the group consisting of Alemtuzumab, Bevacizumab, Cetuximab, Gemtuzumab, Ibritumomab, Panitumumab, Rituximab, Tositumomab, Trastuzumab, and Palivizumab. 44. The composition of claim 5, wherein said antibody or antigen-binding fragment thereof is linked to said .beta.-1-6-glucan via a covalent linkage. 45. The composition of claim 10, wherein said antibody or antigen-binding fragment thereof is linked to said .beta.-1-6-glucan via a covalent linkage.

Details for Patent 8,580,253

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Genentech, Inc.	RITUXAN	rituximab	Injection	103705	11/26/1997		2026-11-06
Idec Pharmaceuticals Corp.	RITUXAN	rituximab	Injection	103737	02/19/2002		2026-11-06
Swedish Orphan Biovitrum Ab (publ)	SYNAGIS	palivizumab	For Injection	103770	06/19/1998		2026-11-06
Swedish Orphan Biovitrum Ab (publ)	SYNAGIS	palivizumab	Injection	103770	07/23/2004		2026-11-06
Genentech, Inc.	HERCEPTIN	trastuzumab	For Injection	103792	09/25/1998		2026-11-06
Genentech, Inc.	HERCEPTIN	trastuzumab	For Injection	103792	02/10/2017		2026-11-06